Search Clinical Trials
Sponsor Condition of Interest |
---|
Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos
San Diego State University
SARS-CoV-2 Infection
This study will examine the effectiveness of a 6-week behavioral intervention for
patients who are recently diagnosed with COVID-19. Patients and their households will be
randomized to one of two groups (Standard of Care vs. Enhanced Standard of Care).
Patients in the Standard-of-Care group will receive... expand
This study will examine the effectiveness of a 6-week behavioral intervention for patients who are recently diagnosed with COVID-19. Patients and their households will be randomized to one of two groups (Standard of Care vs. Enhanced Standard of Care). Patients in the Standard-of-Care group will receive established clinical care and follow-up. Patients in the Enhanced Standard-of-Care group will receive standard-of-care plus tailored, real-time text messaging and virtual counseling delivered by promotores/as. The investigators hypothesize that households in the Enhanced Standard-of-Care group will have fewer (any new) household COVID-19 infectivity rates compared to households in the standard-of-care group post-intervention. Type: Interventional Start Date: Apr 2022 |
Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia
University of California, Los Angeles
Long COVID
Dysautonomia
The current pilot study will recruit participants experiencing new, returning, or ongoing
symptoms related to COVID-19 illness for at least four weeks after being first infected
with SARS-CoV-2. All participants will attend a virtual 6-week course entitled Mindful
Awareness Practices (MAPs) created,... expand
The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2. All participants will attend a virtual 6-week course entitled Mindful Awareness Practices (MAPs) created, hosted and led by expert facilitators from the Mindful Awareness Research Center (MARC) at University of California Los Angeles (UCLA). This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. The research team will collect self-reported measures of mental health symptoms, physical health symptoms, and demographic information before and after participants attend MAPs. Objective health measures will also be collected by the research team including an active stand test, a 6-minute walk, and a blood sample. Type: Interventional Start Date: Feb 2023 |
Lupus Education Alliance Program
Tulane University
Systemic Lupus Erythematosus
COVID-19
The purpose of this study is to evaluate the evaluate the effect of education-only vs.
navigation interventions on COVID-19 testing and vaccination for people with systemic
lupus erythematosus. expand
The purpose of this study is to evaluate the evaluate the effect of education-only vs. navigation interventions on COVID-19 testing and vaccination for people with systemic lupus erythematosus. Type: Interventional Start Date: Nov 2023 |
Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate
University of Pennsylvania
Covid19
The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19
(FERMIN) trial is being executed. The trial is testing a short intervention (10 days of
fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this
sub-study is to explore the impact of fenofibrate... expand
The International multicenter FEnofibRate as a Metabolic INtervention for COVID-19 (FERMIN) trial is being executed. The trial is testing a short intervention (10 days of fenofibrate therapy) on 30-day outcomes in COVID-19. The overarching goal of this sub-study is to explore the impact of fenofibrate on key longer term phenotypes of vascular, cardiac and pulmonary health, integrated cardiopulmonary function, persistent/chronic symptoms and quality of life. Type: Observational Start Date: Aug 2021 |
Multisite Observational Maternal and Infant Study for COVID-19
Emory University
COVID-19
This is an observational, non-interventional, prospective cohort study designed to
collect clinical information and specimens to evaluate the immune responses from pregnant
individuals and postpartum individuals and their infants following maternal receipt of
licensed or Emergency Use Authorization... expand
This is an observational, non-interventional, prospective cohort study designed to collect clinical information and specimens to evaluate the immune responses from pregnant individuals and postpartum individuals and their infants following maternal receipt of licensed or Emergency Use Authorization (EUA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. Type: Observational Start Date: Jul 2021 |
Post Acute Sequelae of COVID-19
Vanderbilt University Medical Center
Covid19
Sars-CoV-2 Infection
Dyspnea Caused by 2019-nCoV
COVID-19 Acute Respiratory Distress Syndrome
Pulmonary Fibrosis
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it
emerged in 2019. There is ongoing research and growing literature describing severe acute
respiratory syndrome (SARS-COV-2). There is a growing population of individuals who have
recovered from acute SARS-COV-2 infection.... expand
COVID-19, a novel coronavirus, has caused widespread mortality and morbidity since it emerged in 2019. There is ongoing research and growing literature describing severe acute respiratory syndrome (SARS-COV-2). There is a growing population of individuals who have recovered from acute SARS-COV-2 infection. The long-term effects of COVID-19 are unknown. There are growing reports of sequelae after acute SARS-CoV-2 not limited to fatigue, dyspnea, reactive airway disease, organizing pneumonia, pulmonary fibrosis, pulmonary hypertension, pulmonary emboli, and tracheal disease. The incidence and natural history of these findings is unstudied. Type: Observational [Patient Registry] Start Date: Aug 2021 |
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
Janssen Vaccines & Prevention B.V.
COVID-19 Prevention
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral
immune responses after 6 dose levels of Ad26.COV2.S. expand
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S. Type: Interventional Start Date: Jun 2021 |
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Connecticut Children's Medical Center
COVID-19
SARS-CoV-2
Inflammatory Bowel Diseases
Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprised
of heterogeneous populations with a large risk spectrum for more severe disease.
Pre-existing risk factors for a more severe course include respiratory and cardiovascular
disease, morbid obesity, diabetes, underlying... expand
Individuals susceptible to SARS-CoV-2 and the illness it causes (COVID-19) are comprised of heterogeneous populations with a large risk spectrum for more severe disease. Pre-existing risk factors for a more severe course include respiratory and cardiovascular disease, morbid obesity, diabetes, underlying kidney or liver disease, and immunocompromised status. Whether children and young adults with inflammatory bowel disease (IBD) or juvenile idiopathic arthritis (JIA) receiving immunomodulating biologic and other therapies which are known to increase risk of viral infection are at increased risk of complications from COVID-19 or post-infectious co-morbidities, including the recently described multi inflammatory syndrome (MISC), is entirely unclear. This research focuses on the heretofore uncharacterized immune response to SARS-CoV-2 infection in children and young adults with IBD or JIA who are receiving maintenance immunosuppressive biologic therapies. Given the large Connecticut based infusion program, in a region of the United States with a recent large outbreak of COVID-19, the investigators have a unique opportunity to address a glaring knowledge gap in this unique pediatric, adolescent, and young adult population. The investigators will longitudinally determine antibody development and durability to SARS-CoV-2 in approximately 450-500 children and young adults with IBD or JIA receiving biologic therapy using a highly sensitive and specific quantitative assay utilizing novel technology. This period will include a return to school or work for many with likely resurgent infections, as well as the possible introduction of anti-SARS CoV-2 vaccines. The specific aim is to study the acute and convalescent antibody responses to SARS-CoV-2 infection in a cohort of children and young adults receiving infusions of biologic therapies for IBD and JIA. Type: Observational Start Date: May 2020 |
Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce
M.D. Anderson Cancer Center
COVID-19 Infection
This study investigates the impact of the COVID-19 pandemic on the psychosocial health of
employees of MD Anderson Cancer Center. Epidemics have been shown to promote
psychological stress among medical staff in high risk areas, which may lead to mental
health problems. Assessing how the pandemic is... expand
This study investigates the impact of the COVID-19 pandemic on the psychosocial health of employees of MD Anderson Cancer Center. Epidemics have been shown to promote psychological stress among medical staff in high risk areas, which may lead to mental health problems. Assessing how the pandemic is affecting employees may allow for more comprehensive actions to be taken to protect the mental health of employees. Type: Observational Start Date: May 2020 |
A Study of N-acetylcysteine in Patients With COVID-19 Infection
Memorial Sloan Kettering Cancer Center
Covid-19
The study researchers think that a medication called N-acetylcysteine can help fight the
COVID-19 virus by boosting a type of cell in your immune system that attacks infections.
By helping your immune system fight the virus, the researchers think that the infection
will get better, which could allow... expand
The study researchers think that a medication called N-acetylcysteine can help fight the COVID-19 virus by boosting a type of cell in your immune system that attacks infections. By helping your immune system fight the virus, the researchers think that the infection will get better, which could allow the patient to be moved out of the critical care unit or go off a ventilator, or prevent them from moving into a critical care unit or going on a ventilator. The US Food and Drug Administration (FDA) has approved N-acetylcysteine to treat the liver side effects resulting from an overdose of the anti-inflammatory medication Tylenol® (acetaminophen). N-acetylcysteine is also used to loosen the thick mucus in the lungs of people with cystic fibrosis or chronic obstructive pulmonary disease (COPD). This study is the first to test N-acetylcysteine in people with severe COVID-19 infections. Type: Interventional Start Date: May 2020 |
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children...
Duke University
Coronavirus Infection (COVID-19)
Pulmonary Arterial Hypertension
Urinary Tract Infections in Children
Hypertension
Pain
The study investigators are interested in learning more about how drugs, that are given
to children by their health care provider, act in the bodies of children and young adults
in hopes to find the most safe and effective dose for children. The primary objective of
this study is to evaluate the PK... expand
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider. Type: Observational Start Date: Mar 2020 |
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
National Institute of Neurological Disorders and Stroke (NINDS)
Systemic Inflammation
Neuroinflammation
Microvascular Thrombosis
Background:
COVID-19 can cause problems in different parts of the body. For most people, it causes
fevers or trouble breathing. Some people might not recover all the way. Researchers want
to see if a treatment can help with people who have recovered from COVID-19 but still
have symptoms ("Long... expand
Background: COVID-19 can cause problems in different parts of the body. For most people, it causes fevers or trouble breathing. Some people might not recover all the way. Researchers want to see if a treatment can help with people who have recovered from COVID-19 but still have symptoms ("Long COVID"). Objective: To learn if human immunoglobulin (IVIG) will help with neurological symptoms of Long COVID. Eligibility: Adults ages 18 and older who had COVID-19 at least 12 weeks ago and have ongoing neurologic symptoms, such as dizziness, trouble walking, or problems with strength. Design: Participants will be screened with a medical record review. Participants will have a medical history and a physical exam and complete questionnaires about their health and quality of life. They will have a spinal tap. They will give blood samples. They will discuss their symptoms with a neurologist and have a neurological exam. Participants will take memory and thinking tests using a tablet. The tests will take 1 hour to complete. They will also take a smell and taste test. It will take approximately 30 minutes to complete. Participants will lie on a table that tilts for up to 40 minutes. Their blood pressure and heart rate will be monitored. Blood will be taken through an intravenous (IV) catheter. Participants will receive either IVIG, or saline by IV for 5 days. Then the participants will receive IVIG if they first received saline or saline if they first received IVIG by IV for another 5 days. They will not know what they receive. Participants will have an MRI of the brain if they have not had one recently. They will receive a contrast agent by IV as part of the MRI scan. Participants will be on the study for up to 4 months. They will have follow-up visits at the clinical center as well as fill out questionnaires at home. They may be asked to continue follow-up.... Type: Interventional Start Date: Jul 2023 |
Mechanisms Underlying Cardiovascular Consequences Associated With COVID-19 and Long COVID
Columbia University
COVID-19
AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary,
meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular
vasomotor function.
AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated
with microvascular... expand
AIM 1. Characterize cardiovascular phenotypes of long COVID by cardiopulmonary, meta-bolic, and cardiac mechanical/physiological responses to exercise and microvascular vasomotor function. AIM 2. Identify intercellular signaling between immune cells and cardiac cells associated with microvascular phenotypes of long COVID. Type: Observational Start Date: Mar 2022 |
Evaluating Emetine for Viral Outbreaks (EVOLVE)
Johns Hopkins University
COVID-19
The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety
of emetine administered orally for symptomatic Covid-19 patients in patients ages 30
years and above. Participants will be asked to:
- Take Emetine 6mg orally for 10 consecutive days
- Be monitored... expand
The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to: - Take Emetine 6mg orally for 10 consecutive days - Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms - Undergo blood draws Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19. Type: Interventional Start Date: May 2024 |
T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19
Duke University
COVID-19 Acute Respiratory Distress Syndrome
T-Cell Mitochondrial Respiration Response to Ketone monoester (Ketoneaid) in Healthy
Volunteers and COVID-19 expand
T-Cell Mitochondrial Respiration Response to Ketone monoester (Ketoneaid) in Healthy Volunteers and COVID-19 Type: Observational Start Date: Jun 2024 |
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe...
Pfizer
COVID-19
The purpose of this study is to learn about the side effects (safety) of the study
medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate
COVID-19 infection in adults with severe renal impairment. The study will also look at
the amounts of study drug in your blood. There... expand
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment. The study will also look at the amounts of study drug in your blood. There will be 24 participants in this study; 12 of them will have severe renal impairment and not be on hemodialysis and 12 of them will be on hemodialysis. All participants in this study will take PF-07321332 (nirmatrelvir)/ritonavir by mouth for 5 days. During this time, they will have to collect blood samples to measure the study drug levels in their blood. After taking the study drug for 5 days, the participants will have follow-up visits for about another 28 days for a total of about 34 days in the study. The study team will check how each participant is doing during regular visits at the study clinic. Type: Interventional Start Date: Sep 2022 |
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the...
University of Michigan
COVID-19
Corona Virus Infection
This study will evaluate the safety of administering an additional dose of an mRNA
COVID-19 vaccine or mRNA bivalent COVID-19 booster vaccine to individuals who have had
adverse reactions to a previous dose or administering an initial dose of an mRNA COVID-19
vaccine to individuals with a personal... expand
This study will evaluate the safety of administering an additional dose of an mRNA COVID-19 vaccine or mRNA bivalent COVID-19 booster vaccine to individuals who have had adverse reactions to a previous dose or administering an initial dose of an mRNA COVID-19 vaccine to individuals with a personal history of allergic reaction. In addition, this study will evaluate the safety of administering an initial or additional dose or bivalent booster of an mRNA COVID-19 vaccine to individuals experiencing an adverse reaction to a natural COVID-19 infection ("long COVID"). Eligible participants enrolled in this trial will receive an initial or additional dose of either the Pfizer-BioNTech COVID-19 bivalent vaccine or the Moderna COVID-19 bivalent vaccine. Participants will also be required to have 1-2 in person visits along with phone call follow up visits. We hypothesize that individuals who have had adverse reactions to a previous dose of an mRNA COVID-19 vaccine will tolerate an additional dose of the primary mRNA vaccine or bivalent booster, as indicated, and those with a personal history of allergic reaction will tolerate an initial dose of an mRNA COVID-19 vaccine. We also hypothesize that those individuals experiencing an adverse reaction will tolerate an initial or additional dose of a primary mRNA COVID-19 bivalent vaccine, as indicated. The study hypothesizes that individuals that have had adverse reactions to a dose of an mRNA COVID-19 vaccine will tolerate an additional dose and those with a personal history of allergic reaction will tolerate vaccination with an mRNA COVID-19 vaccine. Type: Interventional Start Date: Mar 2022 |
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as...
Emergent BioSolutions
SARS-CoV-2 Infection
The primary objectives of this open-label trial were to evaluate the safety and
pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product
(COVID-HIG) administered intramuscularly (IM), subcutaneously (SC), or intravenously (IV)
as a single dose in healthy adults 18-59... expand
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously (SC), or intravenously (IV) as a single dose in healthy adults 18-59 years of age with body mass index ≤35 kg/m^2. Prior studies examined IV administration, and the secondary objective of the present study was to compare PK among the three administration routes. No placebo group was included in the phase 1 randomized design. The exploratory objective was to evaluate disease severity in participants that became positive for SARS-CoV-2. Type: Interventional Start Date: Dec 2021 |
Safe and Healthy Schools
University of Wisconsin, Madison
Sars-CoV-2 Infection
COVID-19
This study will target Madison Metropolitan School District (MMSD) school children ages
4-19 and staff who have not had a previous positive COVID-19 test within the past 3
months. It will enroll children and adults for 1-3 days to explore whether serial
"at-home" BinaxNOW testing is feasible and non-inferior... expand
This study will target Madison Metropolitan School District (MMSD) school children ages 4-19 and staff who have not had a previous positive COVID-19 test within the past 3 months. It will enroll children and adults for 1-3 days to explore whether serial "at-home" BinaxNOW testing is feasible and non-inferior to "at school" single PCR testing for the evaluation of symptomatic individuals with a negative initial BinaxNOW. It will also explore whether lollipop swabs are more acceptable and perform as well as nasal swabs with polymerase chain reaction (PCR) testing. Type: Interventional Start Date: Oct 2021 |
Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound
University of Louisville
Covid19
Echocardiography
Ultrasound
We hypothesize that recovered COVID-19 patients suffer long term cardiovascular and
pulmonary complications, which can be detected by point of care ultrasound. The goal is
to comprehensively delineate the long term cardiovascular and pulmonary ultrasound
findings in recovered COVID-19 patients, identify... expand
We hypothesize that recovered COVID-19 patients suffer long term cardiovascular and pulmonary complications, which can be detected by point of care ultrasound. The goal is to comprehensively delineate the long term cardiovascular and pulmonary ultrasound findings in recovered COVID-19 patients, identify risks factors for prolonged heart/lung injury, evaluate long term effects of applied treatment, and assess late medication/vaccine side effects in COVID-19 patients. Type: Observational Start Date: Apr 2021 |
Defibrotide for the Treatment of Severe COVID-19
Brigham and Women's Hospital
Covid19
The goal of this study is to evaluate the safety and feasibility of defibrotide in
COVID-19 pneumonia. expand
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia. Type: Interventional Start Date: Jan 2021 |
Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During...
Washington University School of Medicine
Covid19
Intellectual Disability
Developmental Disability
Child Development Disorder
The primary goal of this project is to identify the best messaging and implementation
strategies to maximize SARS-CoV-2 testing for children with intellectual and
developmental disabilities (IDD) and their teachers to help ensure a safe school
environment. Additionally, we will understand nationally... expand
The primary goal of this project is to identify the best messaging and implementation strategies to maximize SARS-CoV-2 testing for children with intellectual and developmental disabilities (IDD) and their teachers to help ensure a safe school environment. Additionally, we will understand nationally the perceptions of COVID-19 and identify facilitators and barriers to help with the adoption of testing in other parts of the US and the necessary strategies to address other mitigation strategies including vaccination. Type: Interventional Start Date: Nov 2020 |
COVID-19 Risk Reduction Among African American Parishioners
Charles Drew University of Medicine and Science
Coronavirus
African American adults, specifically those managing chronic disease and social
isolation, are one of the most vulnerable groups susceptible to COVID-19. This
intervention involves a multi-disciplinary and culturally sensitive approach to address
two major COVID-19 related challenges in this population.... expand
African American adults, specifically those managing chronic disease and social isolation, are one of the most vulnerable groups susceptible to COVID-19. This intervention involves a multi-disciplinary and culturally sensitive approach to address two major COVID-19 related challenges in this population. First, this program collaborates with predominantly African American churches to implement Federal and State guidelines aimed at preventing outbreaks of COVID-19 at faith-based gatherings. Second, this program trains church-based health advisors to help African American older parishioners manage their chronic health conditions and reduce psychological distress during the pandemic. Type: Interventional Start Date: Jun 2021 |
S-Nitrosylation Therapy of COVID-19
James Reynolds
SARS-CoV2 Infection
Covid19
The primary objective of this study is to provide expanded access of S-nitrosylation
therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2)
infection. expand
The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection. Type: Interventional Start Date: Aug 2021 |
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
M.D. Anderson Cancer Center
COVID-19 Infection
Melanoma
The primary purpose of this study is to gain an understanding of how experiences during
the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains
of health-related quality of life and other areas such as COVID-19 specific psychological
distress, and disruptions to health... expand
The primary purpose of this study is to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domains of health-related quality of life and other areas such as COVID-19 specific psychological distress, and disruptions to health care, finances and social interactions. We will also evaluate the extent to which resiliency factors such as social support, perceived benefits under times of stress, and ability to manage stress may buffer associations between COVID-19 experiences and HRQoL. To meet these objectives, we have developed a 10-minute questionnaire that taps into these areas and is based on prior work addressing concerns of other pandemics or national crises. Participants will have previously consented to protocol PA15-0336 and have provided prior lifestyle data. This will allow us to connect the COVID-19 survey data with prior existing data. Type: Observational Start Date: Jun 2020 |
- Previous
- Next